Abstract
Prostate cancer is the most commonly diagnosed non-cutaneous cancer in adult males. Although prostate cancer that is confined to the gland can be cured in many patients using surgery or radiation, these treatments are only effective for localized tumors and the long-term failure rates for these treatments suggests that prostate cancer can metastasize relatively early in the course of the disease. Once prostate cancer has metastasized there are no curative therapies. The greatest challenge in the treatment of advanced prostate cancer is to access and eliminate metastatic cells. Therefore, effective prostate cancer therapy will require novel strategies to target cancer cells both at the site of the primary tumor and at distant metastatic sites. In this article we review several therapeutic targets and approaches that may provide new treatments for metastatic prostate cancer. We discuss the use of small molecules to target specific molecular events associated with metastatic prostate cancer, the use of specific antibodies that target unique metastasis associated molecules and the use of various gene therapy strategies to achieve anti-metastatic activities.
Keywords: gene therapy, Immunotherapy, antibody therapy, rtvp, caveolin, interleukin-12
Current Drug Targets
Title: Therapeutic Targets for Metastatic Prostate Cancer
Volume: 4 Issue: 3
Author(s): Terry L. Timme, Takefumi Satoh, Salahaldin A. Tahir, Hongyu Wang, Bin S. The, E. Brian Butler, Brian J. Miles, Robert J. Amato, Dov Kadmon and Timothy C. Thompson
Affiliation:
Keywords: gene therapy, Immunotherapy, antibody therapy, rtvp, caveolin, interleukin-12
Abstract: Prostate cancer is the most commonly diagnosed non-cutaneous cancer in adult males. Although prostate cancer that is confined to the gland can be cured in many patients using surgery or radiation, these treatments are only effective for localized tumors and the long-term failure rates for these treatments suggests that prostate cancer can metastasize relatively early in the course of the disease. Once prostate cancer has metastasized there are no curative therapies. The greatest challenge in the treatment of advanced prostate cancer is to access and eliminate metastatic cells. Therefore, effective prostate cancer therapy will require novel strategies to target cancer cells both at the site of the primary tumor and at distant metastatic sites. In this article we review several therapeutic targets and approaches that may provide new treatments for metastatic prostate cancer. We discuss the use of small molecules to target specific molecular events associated with metastatic prostate cancer, the use of specific antibodies that target unique metastasis associated molecules and the use of various gene therapy strategies to achieve anti-metastatic activities.
Export Options
About this article
Cite this article as:
Timme L. Terry, Satoh Takefumi, Tahir A. Salahaldin, Wang Hongyu, The S. Bin, Butler Brian E., Miles J. Brian, Amato J. Robert, Kadmon Dov and Thompson C. Timothy, Therapeutic Targets for Metastatic Prostate Cancer, Current Drug Targets 2003; 4 (3) . https://dx.doi.org/10.2174/1389450033491127
DOI https://dx.doi.org/10.2174/1389450033491127 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Subject Index To Volume 6
Endocrine, Metabolic & Immune Disorders - Drug Targets Metals and Metal Derivatives in Medicine
Mini-Reviews in Medicinal Chemistry Marizomib, A Potent Second Generation Proteasome Inhibitor from Natural Origin
Anti-Cancer Agents in Medicinal Chemistry Systemic Lupus Erythematosus: Old and New Susceptibility Genes versus Clinical Manifestations
Current Genomics Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Targeting Tumor Proteasome with Traditional Chinese Medicine
Current Drug Discovery Technologies Review of the Contribution of Radiolabelled Tracers for Tumour Cell Status Imaging
Current Medical Imaging Bioinformatic Tools Identify Chromosome-Specific DNA Probes and Facilitate Risk Assessment by Detecting Aneusomies in Extra-embryonic Tissues
Current Genomics Cancer Resistance to Type II Topoisomerase Inhibitors
Current Medicinal Chemistry Antitumor Activity of Magnetite Nanoparticles: Influence of Hydrocarbonated Chain of Saturated Aliphatic Monocarboxylic Acids
Current Organic Chemistry C-1073 (Mifepristone) in the Adjunctive Treatment of Alzheimers Disease
Current Alzheimer Research Human 90 kDa Heat Shock Protein Hsp90 as a Target for Cancer Therapeutics
Current Chemical Biology RAS Pathways in Prostate Cancer - Mediators of Hormone Resistance?
Current Cancer Drug Targets Editorial
Recent Patents on Anti-Cancer Drug Discovery Colchicine: An Old Wine in a New Bottle?
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cancer-Homing Toxins
Current Pharmaceutical Design Labeling Strategies of Peptides with 18F for Positron Emission Tomography
Current Topics in Medicinal Chemistry Protein Kinase CK2 in Human Diseases
Current Medicinal Chemistry Steroid Hybrid Systems: New Molecular Entities with Potential Therapeutical Spectrum
Current Drug Therapy The Family B1 GPCR: Structural Aspects and Interaction with Accessory Proteins
Current Drug Targets